18
Participants
Start Date
December 31, 2015
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
PF-04136309
"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
Pfizer Clinical Research Unit, Brussels
Lead Sponsor
Pfizer
INDUSTRY